Talking PointTalking Point is a regular series of publicly available lectures that aim to inspire, inform and challenge our notions of what we know about addiction and its impact across society. Health and social sector professionals and the general public are all welcome to attend. |
|
64 items
- presented by Dr Emily Hennesy on 6th November 2025
Stable recovery during adolescence requires more than the cessation of substance use—it requires access to social, psychological, and community resources collectively known as recovery capital. - presented by Professor Billie Bonevski on 29th October 2025
E-cigarettes containing nicotine (e-cigarettes) have demonstrated effectiveness for smoking cessation among general populations, but limited evidence in people with substance use disorders (SUD). - presented by Julain Allen and Jacqui Cameron on 3rd September 2025
Nitrous Oxide (N2O), colloquially known as “laughing gas” or “nangs”, is a dissociative anaesthetic that has become increasingly popular among young people. - presented by Dr Bosco Rowland on 27th August 2025
Originating in the US, Communities that Care is a public health prevention framework that has been operating in Australia for 25 years. - presented by Tanya Saraiya on 7th August 2025
Up to 90% of people with opioid use disorder (OUD) have trauma exposure and up to 41% have post-traumatic stress disorder (PTSD). - presented by Clare Slattery on 30th July 2025
Law is one of the most effective policy tools to address alcohol-related harm. - presented by Dr Nadine Ezard
We conducted a randomised double-blind placebo controlled trial of 250mg lisdexamfetamine daily vs placebo among 164 adults with methamphetamine dependence at 6 outpatient services around Australia. - presented by Peter Higgs (PhD, BSW) is a Burnet Principal Research Fellow and Honorary in the Department of Public Health at La Trobe University.
In this presentation findings and insights collected from participants will be presented as well as reflections from me on being involved with such a unique study for the last 15 years.
- presented by Dr Shelly Greenfield, MD, MPH
This presentation will review trends in the epidemiology of gender differences in the prevalence of substance use and substance use disorders in the U.S. - presented by Dr Paul Liknaitzky, Head of the Clinical Psychedelic Lab, and Senior Research Fellow within the Dept of Psychiatry at Monash University
Psilocybin-assisted psychotherapy has shown promising safety and efficacy in treating depression, substance use disorders, and end-of-life distress.